Table 2.
Baseline characteristics of the participants.
| Variable | Non-CVD group (n = 36) | SAP group (n = 76) | STEMI group (n = 61) | p value | ||
|---|---|---|---|---|---|---|
| Non-CVD vs. SAP | Non-CVD vs. STEMI | SAP vs. STEMI | ||||
| Sex, m/f (%) | 29/7 (80/20) | 65/11 (86/14) | 50/11 (82/18) | |||
| Age, years | 34 [26–44] | 64 [58–71] | 58 [54–66] | < 0.0001 | < 0.05 | 0.10 |
| Height, m | 1.67 [1.62–1.72] | 1.69 [1.64–1.75] | 1.72 [1.68–1.76] | 0.21 | 0.11 | 0.72 |
| Weight, kg | 69.0 [59.0–81.0] | 84.4 [70.0–89.0] | 85.3 [72.0–90.0] | < 0.0001 | < 0.001 | 0.57 |
| BMI, kg/m2 | 24.6 [20.7–27.4] | 29.5 [25.6–31.63] | 28.8 [24.9–31.2] | < 0.0001 | < 0.01 | 0.65 |
| Heart rate/min | 62.2 ± 10.8 | 65.8 ± 9.2 | 75.9 ± 14.7 | 0.51 | < 0.05 | < 0.05 |
| Systolic BP, mm Hg | 119.5 ± 5.6 | 120.3 ± 6.9 | 118.6 ± 8.2 | 0.82 | 0.59 | 0.62 |
| Diastolic BP, mm Hg | 75.9 ± 6.2 | 74.7 ± 5.9 | 74.7 ± 7.2 | 0.78 | 0.65 | 0.95 |
| STEMI localization | ||||||
| Anterior wall infarction | n/a | n/a | 26 (42.7) | n/a | n/a | n/a |
| Inferior wall infarction | 34 (55.7) | |||||
| Other | 1 (1.6) | |||||
| Troponin I, ng/ml | 0.001 [0.00–0.005] | 0.05 [0.02–0.07] | 0.29 [0.08–1.03] | < 0.05 | < 0.001 | < 0.05 |
| Total cholesterol, mmol/l | 5.27 [4.81–5.93] | 5.55 [4.50–6.20] | 5.51 [4.62–6.21] | 0.48 | 0.47 | 0.89 |
| Triglycerides, mmol/l | 1.10 [0.76–1.28] | 1.73 [0.96–2.18] | 1.82 [1.01–2.21] | < 0.01 | < 0.01 | 0.51 |
| LDL cholesterol, mmol/l | 3.32 [2.71-4.00] | 3.30 [2.92–4.10] | 3.52 [3.00-4.22] | 0.61 | 0.74 | 0.88 |
| VLDL cholesterol, mmol/l | 0.51 [0.30–0.69] | 1.00 [0.72–1.20] | 0.97 [0.61–1.21] | 0.01 | 0.01 | 0.95 |
| HDL cholesterol, mmol/l | 1.51 [1.22–1.78] | 1.08 [0.89–1.19] | 1.22 [1.01–1.42] | < 0.001 | < 0.01 | < 0.05 |
| Glucose, mmol/l | 4.88 [4.59–5.30] | 5.65 [4.70–5.88] | 10.1* [7.4–10.9] | < 0.01 | < 0.001 | < 0.001 |
| Creatinine, µmol/l | 89.1 [79.4–97.2] | 100.5 [85.5-111.6] | 75.5 [62.5–85.6] | 0.01 | 0.01 | < 0.001 |
| Urea, mmol/l | 6.1 [6.1–6.3] | 6.5 [5.3–7.4] | 6.1 [5.0–7.1] | 0.85 | 0.66 | 0.23 |
| ALT, u/l | 23.0 [20.0–24.0] | 29.0 [20.0–34.5] | 51.0 [24.3–60.7] | 0.31 | < 0.01 | < 0.01 |
| AST, u/l | 25.0 [23.0–27.0] | 36.0 [20.0–36.0] | 159.1 [32–232] | 0.66 | < 0.01 | < 0.01 |
| CPK, u/L | 10.2 ± 2.8 | 50.3 ± 12.1 | 328.4 ± 505.6 | < 0.05 | < 0.001 | < 0.001 |
| CPK-MV, u/L | 3.1 ± 1.2 | 10.8 ± 3.7 | 39.8 ± 59.9 | < 0.05 | < 0.001 | < 0.001 |
| Potassium, mmol/l | 4.63 [4.30–4.90] | 4.41 [4.10–4.65] | 3.72 [3.35–3.96] | < 0.05 | < 0.001 | < 0.001 |
| Sodium, mmol/l | 142.8 [141–145] | 140.0 [138.0-142.2] | 142.1 [141.0-143.7] | 0.12 | 0.76 | 0.08 |
| Calcium, mmol/l | – | 2.18 [2.10–2.23] | 0.91 [0.81–1.01] | – | – | < 0.01 |
| INR | 1.09 [1.05–1.14] | 1.23 [1.11–1.28] | 1.13 [1.01–1.23] | < 0.05 | 0.53 | 0.05 |
| APTT, s | 27.2 [25.5–28.6] | 31.5 [27.0-34.8] | 42.0 [28.9–74.0] | 0.19 | < 0.05 | < 0.05 |
| Fibrinogen, g/L | 2.25 [2.05–2.30] | 3.28 [2.53–3.74] | 3.40 [3.10–4.10] | < 0.05 | < 0.01 | 0.21 |
| LVEF, % | 59.8 [60.2–64.5] | 53.2 [45.0–60.0] | 49.2 [39.0-52.3] | 0.08 | < 0.01 | 0.05 |
Baseline characteristics of the participants, including n (%) or median and interquartile range [Q1; Q3], in the considered groups and corresponding p values indicating statistically significant differences between groups.
*Hyperglycaemia is due to nonfasting blood samples obtained before angiography in STEMI patients.